Dive into the future of ethical research where CytoSolve®’s advanced computational modeling is reshaping scientific exploration, offering a vital alternative to animal testing.
Be part of this transformative dialogue and help drive the change towards more ethical, efficient scientific practices. Let’s redefine the future of research together. Even organizations like the FDA have concluded that there is no reason for animal testing.
The CytoSolve® Open Science Institute™ is dedicated to advancing health by fundamentally opening science to ALL OF US. The CytoSolve® platform makes this a reality.
Donate to support CytoSolve® Open Science Institute™ dedicated to delivering medicines from Nature and a force to topple Big Pharma.
The CytoSolve® Open Science Institute™ is dedicated to advancing health by fundamentally opening science to ALL OF US. The CytoSolve® platform makes this a reality.
Introduction: A Paradigm Shift in Addressing Diabetes
Diabetes is a global health crisis with projections indicating that over 1.3 billion people will be affected by 2050. Despite billions of dollars spent on research, the prevalence of diabetes continues to rise, demonstrating that the current approaches are not solving the problem.
At the 11th CytoSolve® Symposium on Diabetes, Dr. Shiva Ayyadurai and his team outlined a systems-based approach to understand diabetes—a radical departure from the pharmaceutical-driven, reductionist view of modern medicine. CytoSolve®, a revolutionary computational biology platform, is uncovering natural, evidence-based solutions for diabetes management while exposing the failures of conventional drug-centric interventions.
This blog post provides a comprehensive overview of diabetes, its molecular pathways, current treatments, and how CytoSolve® is pioneering a breakthrough approach that leverages natural compounds, computational modeling, and systems thinking to provide effective solutions.
What is Diabetes?
Understanding the Disease at a Molecular Level
Diabetes mellitus, often referred to simply as diabetes, is a chronic metabolic disorder characterized by elevated blood glucose levels (hyperglycemia) due to insulin dysfunction. There are two major types:
Type 1 Diabetes (T1D): An autoimmune condition where the pancreas fails to produce insulin due to the destruction of beta cells.
Type 2 Diabetes (T2D): A metabolic disorder where the body produces insulin but does not respond properly to it, leading to insulin resistance.
The Role of Insulin in Glucose Metabolism
Insulin, produced by the beta cells of the pancreas, regulates blood glucose levels by:
Promoting glucose uptake by muscle and fat cells.
Suppressing glucose production in the liver.
Inhibiting fat breakdown that leads to the release of free fatty acids.
In Type 2 diabetes, insulin fails to regulate these processes effectively, resulting in persistently high blood glucose levels that damage multiple organs, including the heart, kidneys, and nerves.
Insulin Mechanism – Diagram Showing Insulin and Glucose Uptake
The Crisis: Why Are Diabetes Rates Still Rising?
According to a 2023 Lancet study, diabetes prevalence is expected to reach 1.3 billion people by 2050, with the highest rates in North Africa, the Middle East, and Latin America. Despite decades of pharmaceutical interventions, diabetes rates continue to rise, raising a crucial question:
Are conventional treatments truly solving the problem, or are they designed to sustain a profitable industry?
The Failure of Big Pharma’s Reductionist Approach
The pharmaceutical industry has developed highly lucrative diabetes drugs, but these treatments do not address the root cause of the disease. Here are some of the top-selling diabetes drugs:
Drug
Sales (Billion USD)
Ozempic
8.73
Jardiance
8.3
Trulicity
7.0
These drugs primarily suppress symptoms rather than restoring metabolic balance. The CytoSolve® Symposium highlighted how a systems approach, which integrates food, lifestyle, and molecular-level research, is crucial for true health solutions.
The Systems Biology Approach: How CytoSolve® is Revolutionizing Diabetes Research
CytoSolve® is a computational systems biology platform developed by Dr. Shiva Ayyadurai at MIT. Unlike traditional pharmaceutical research, which relies on animal testing and isolated clinical trials, CytoSolve® models complex biological interactions at the molecular level to predict the most effective interventions.
Key Features of CytoSolve’s Approach
Mapping the Molecular Pathways of Diabetes
CytoSolve® has identified four key molecular pathways involved in insulin resistance and glucose metabolism:
Berberine: Competes with Ozempic in its ability to regulate blood sugar.
Bitter Melon, Neem, Fenugreek: Traditionally used in Ayurveda for diabetes.
Validating the Effects of Natural Compounds Using CytoSolve®
For example, Cinnamon’s active compound (Cinnamaldehyde) has been computationally validated to increase GLUT4 by 50%, significantly improving glucose metabolism.
Unlike synthetic drugs, these natural interventions work in harmony with the body without causing harmful side effects.
Beyond Treatment: The Root Cause of Diabetes
1. Inflammation and Insulin Resistance
Chronic inflammation, driven by poor diet, sedentary lifestyle, and environmental toxins, is a major contributor to insulin resistance. The arachidonic acid pathway, a key inflammatory process, is directly linked to diabetes progression.
2. The Gut-Glucose Connection
Recent research shows that gut microbiome imbalances contribute to diabetes by affecting:
Inflammation levels
Nutrient absorption
Insulin sensitivity
By addressing gut health through diet, prebiotics, and natural interventions, diabetes management can become significantly more effective.
3. Epigenetics: Reversing Diabetes Naturally
Contrary to popular belief, genetics is not destiny. The emerging field of epigenetics shows that lifestyle choices can turn on or off genes associated with diabetes. CytoSolve® is leveraging precision nutrition to develop personalized health strategies.
A Call to Action: A New Health Revolution
The Need for Decentralized, Systems-Based Healthcare
The CytoSolve® movement is not just about research—it’s about empowering individuals to take control of their health. Unlike pharmaceutical companies, which prioritize profits, CytoSolve’s research is funded by the people, for the people.
By integrating systems thinking, natural medicine, and advanced computational biology, CytoSolve® is leading a health revolution—one that is designed to empower people, not profit-driven industries.
Safety assessment of genetically modified organisms (GMOs) is a contentious topic. Proponents of GMOs assert that GMOs are safe since the FDA’s policy of substantial equivalence considers GMOs “equivalent” to their non-GMO counterparts, and argue that genetic modification (GM) is simply an extension of a “natural” process of plant breeding, a form of “genetic modification”, though done over longer time scales. Anti-GMO activists counter that GMOs are unsafe since substantial equivalence is unscientific and outdated since it originates in the 1970s to assess safety of medical devices, which are not comparable to the complexity of biological systems, and contend that targeted GM is not plant breeding. The heart of the debate appears to be on the methodology used to determine criteria for substantial equivalence. Systems biology, which aims to understand complexity of the whole organism, as a system, rather than just studying its parts in a reductionist manner, may provide a framework to determine appropriate criteria, as it recognizes that GM, small or large, may affect emergent properties of the whole system. Herein, a promising computational systems biology method couples known perturbations on five biomolecules caused by the CP4 EPSPS GM of Glycine max L. (soybean), with an integrative model of C1 metabolism and oxidative stress (two molecular systems critical to plant function). The results predict significant accumulation of formaldehyde and concomitant depletion of glutathione in the GMO, suggesting how a “small” and single GM creates “large” and systemic perturbations to molecular systems equilibria. Regulatory agencies, currently reviewing rules for GMO safety, may wish to adopt a systems biology approach using a combination of in silico, computational methods used herein, and subsequent targeted experimental in vitro and in vivo designs, to develop a systems understanding of “equivalence” using biomarkers, such as formaldehyde and glutathione, which predict metabolic disruptions, towards modernizing the safety assessment of GMOs.
Multiscale Mathematical Modeling to Support Drug Development
DAVID A. NORDSLETTEN, BERACAH YANKAMA, RENATO UMETON, V. A. SHIVA AYYADURAI, AND C. FORBES DEWEY, JR.
IEEE Transactions On Biomedical Engineering, Vol. 58, No. 12, December 2011 DOI: 10.1109/TBME.2011.2173245
Abstract:
It is widely recognized that major improvements are required in the methods currently being used to develop new therapeutic drugs. The time frominitial target identification to commercialization can be 10–14 years and incur a cost in the hundreds of millions of dollars. Even after substantial investment, only 30–40% of the candidate compounds entering clinical trials are successful. We propose that multiscale mathematical pathway modeling can be used to decrease time required to bring candidate drugs to clinical trial and increase the probability that they will be successful in humans. The requirements for multiple time scales and spatial scales are discussed, and new computational paradigms are identified to address the increased complexity of modeling.
Pericytes of the neurovascular unit: key functions and signaling pathways
MELANIE D SWEENEY, SHIVA AYYADURAI & BERISLAV V ZLOKOVIC
Pericytes are vascular mural cells embedded in the basement membrane of blood microvessels. They extend their processes along capillaries, pre-capillary arterioles and post-capillary venules. CNS pericytes are uniquely positioned in the neurovascular unit between endothelial cells, astrocytes and neurons. They integrate, coordinate and process signals from their neighboring cells to generate diverse functional responses that are critical for CNS functions in health and disease, including regulation of the blood–brain barrier permeability, angiogenesis, clearance of toxic metabolites, capillary hemodynamic responses, neuroinflammation and stem cell activity. Here we examine the key signaling pathways between pericytes and their neighboring endothelial cells, astrocytes and neurons that control neurovascular functions. We also review the role of pericytes in CNS disorders including rare monogenic diseases and complex neurological disorders such as Alzheimer’s disease and brain tumors. Finally, we discuss directions for future studies.
Combinatorial drug therapy for cancer in the post-genomic era
Over the past decade, whole genome sequencing and other ‘omics’ technologies have defined pathogenic driver mutations to which tumor cells are addicted. Such addictions, synthetic lethalities and other tumor vulnerabilities have yielded novel targets for a new generation of cancer drugs to treat discrete, genetically defined patient subgroups. This personalized cancer medicine strategy could eventually replace the conventional one-size-fits-all cytotoxic chemotherapy approach. However, the extraordinary intratumor genetic heterogeneity in cancers revealed by deep sequencing explains why de novo and acquired resistance arise with molecularly targeted drugs and cytotoxic chemotherapy, limiting their utility. One solution to the enduring challenge of polygenic cancer drug resistance is rational combinatorial targeted therapy.
In Silico Modeling of Shear-Stress-Induced Nitric Oxide Production in Endothelial Cells through Systems Biology
ANDREW KOO, DAVID NORDSLETTEN, RENATO UMETON, BERACAH YANKAMA, SHIVA AYYADURAI, GUILLERMO GARCIA-CARDENA, AND C. FORBES DEWEY, JR.
Nitric oxide (NO) produced by vascular endothelial cells is a potent vasodilator and an antiinflammatory mediator. Regulating production of endothelial-derived NO is a complex undertaking, involving multiple signaling and genetic pathways that are activated by diverse humoral and biomechanical stimuli. To gain a thorough understanding of the rich diversity of responses observed experimentally, it is necessary to account for an ensemble of these pathways acting simultaneously. In this article, we have assembled four quantitative molecular pathways previously proposed for shear-stress-induced NO production. In these pathways, endothelial NO synthase is activated 1), via calcium release, 2), via phosphorylation reactions, and 3), via enhanced protein expression. To these activation pathways, we have added a fourth, a pathway describing actual NO production from endothelial NO synthase and its various protein partners. These pathways were combined and simulated using CytoSolve, a computational environment for combining independent pathway calculations. The integrated model is able to describe the experimentally observed change in NO production with time after the application of fluid shear stress. This model can also be used to predict the specific effects on the system after interventional pharmacological or genetic changes. Importantly, this model reflects the up-to-date understanding of the NO system, providing a platform upon which information can be aggregated in an additive way.
Services-Based Systems Architecture for Modeling the Whole Cell: A Distributed Collaborative Engineering Systems Approach
Modeling the whole cell is a goal of modern systems biology. Current approaches are neither scalable nor flexible to model complex cellular functions. They do not support collaborative development, are monolithic and, take a primarily manual approach of combining each biological pathway model’s software source code to build one large monolithic model that executes on a single computer. What is needed is a distributed collaborative engineering systems approach that offers massive scalability and flexibility, treating each part as a services-based component, potentially delivered by multiple suppliers, that can be dynamically integrated in real-time. A requirements specification for such a services-based architecture is presented. This specification is used to develop CytoSolve, a working prototype that implements the services-based architecture enabling dynamic and collaborative integration of an ensemble of biological pathway models, that may be developed and maintained by teams distributed globally. This architecture computes solutions in a parallel manner while offering ease of maintenance of the integrated model. The individual biological pathway models can be represented in SBML, CellML or in any number of formats. The EGFR model of Kholodenko with known solutions is first tested within the CytoSolve framework to prove it viability. Success of the EGFR test is followed with the development of an integrative model of interferon (IFN) response to virus infection using the CytoSolve platform. The resulting integrated model of IFN yields accurate results based on comparison with previously published in vitro and in vivo studies. A open web-based environment for collaborative testing and continued development is now underway and available on www.cytosolve.com. As more biological pathway models develop in a disparate and decentralized manner, this architecture offers a unique platform for collaborative systems biology, to build large-scale integrative models of cellular function, and eventually one day model the whole cell.
CytoSolve: A Scalable Computational Method for Dynamic Integration of Multiple Molecular Pathway Models
A grand challenge of computational systems biology is to create a molecular pathway model of the whole cell. Current approaches involve merging smaller molecular pathway models’ source codes to create a large monolithic model (computer program) that runs on a single computer. Such a larger model is difficult, if not impossible, to maintain given ongoing updates to the source codes of the smaller models. This paper describes a new system called CytoSolve that dynamically integrates computations of smaller models that can run in parallel across different machines without the need to merge the source codes of the individual models. This approach is demonstrated on the classic Epidermal Growth Factor Receptor (EGFR) model of Kholodenko. The EGFR model is split into four smaller models and each smaller model is distributed on a different machine. Results from four smaller models are dynamically integrated to generate identical results to the monolithic EGFR model running on a single machine. The overhead for parallel and dynamic computation is approximately twice that of a monolithic model running on a single machine. The CytoSolve approach provides a scalable method since smaller models may reside on any computer worldwide, where the source code of each model can be independently maintained and updated.
